Insider Trading June 16, 2026 08:59 PM

Cigna Chief Accounting Officer Executes Share Sale Following Option Exercise

Jamie Kates disposes of 899 shares at $298.61, realizing a near 95% return on original grant price as the insurer reports strong Q1 results and revises guidance upward.

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
CI

Jamie G. Kates, serving as Chief Accounting Officer at Cigna Group (NYSE:CI), executed a transaction involving the sale of 899 shares of the company's common stock on June 12, 2026. The sale followed the exercise of employee stock options originally granted on February 28, 2018. The options vested in three equal annual installments beginning February 28, 2019. Kates acquired the shares at an exercise price of $152.8947 per share, totaling $137,452. Immediately after acquisition, all 899 shares were sold at $298.612 per share, generating a total sale value of $268,452. This transaction reflects a near 95% gain from the initial option exercise price. Following the sale, Kates retains direct ownership of 2,368 shares of Cigna Group common stock. The transaction occurs as Cigna trades at $291.88, with a price-to-earnings ratio of 12.35, a valuation noted as below typical healthcare sector averages. Cigna has maintained dividend payments for 45 consecutive years, currently offering a 2.14% yield. Recent financial data shows the company surpassed Q1 2026 analyst expectations with adjusted earnings per share of $7.79 against a forecast of $7.61. Revenue also exceeded projections, reaching $68.5 billion compared to the expected $66.2 billion. In response to this performance, Cigna raised its full-year 2026 EPS guidance. Analyst sentiment presents mixed views. Deutsche Bank downgraded the stock rating from Buy to Hold, citing a lack of catalysts and suggesting the company might lag behind other managed care organizations. The price target was adjusted to $302 from $303. Wolfe Research lowered its price target to $315 from $325 but maintained an Outperform rating, noting progress in the transition to a rebate-free Signature model and pharmacy network recontracting.

Cigna Chief Accounting Officer Executes Share Sale Following Option Exercise
CI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Jamie Kates sold 899 shares at $298.612 per share, realizing a near 95% gain from the original $152.8947 exercise price.
  • Cigna reported Q1 2026 adjusted EPS of $7.79, surpassing the $7.61 forecast, with revenue of $68.5 billion against $66.2 billion expected.
  • Analyst sentiment is divided, with Deutsche Bank downgrading to Hold and Wolfe Research lowering its price target to $315 but maintaining an Outperform rating.

On June 12, 2026, Jamie G. Kates, holding the position of Chief Accounting Officer at Cigna Group (NYSE:CI), completed a transaction involving the sale of 899 shares of the company's common stock. This disposition followed the exercise of employee stock options that were initially granted on February 28, 2018. The options were structured to vest in three equal annual installments, with the first vesting date occurring on February 28, 2019.

Kates acquired the 899 shares through the exercise of these options at a price of $152.8947 per share. The total cost for the acquisition was $137,452. Immediately after acquiring the shares, Kates sold all 899 shares at a price of $298.612 per share. This action resulted in a total sale value of $268,452. The sale price represents a near 95% gain from the original option exercise price. Following the transaction, Kates directly holds 2,368 shares of Cigna Group common stock.

The transaction takes place as Cigna trades at $291.88, with a price-to-earnings ratio of 12.35. This valuation is noted as well below typical healthcare sector valuations. Cigna has maintained dividend payments for 45 consecutive years and currently offers a 2.14% yield. The company recently reported its Q1 2026 earnings, surpassing analysts' expectations with an adjusted earnings per share of $7.79, compared to the forecast of $7.61. Revenue also exceeded projections, reaching $68.5 billion against the expected $66.2 billion. In light of this strong financial performance, Cigna has raised its full-year 2026 EPS guidance.

Analyst coverage presents a mixed outlook. Deutsche Bank downgraded Cigna's stock rating from Buy to Hold, citing a lack of catalysts and suggesting that the company might lag behind other managed care organizations. The price target was adjusted to $302 from $303. Wolfe Research also revised its price target for Cigna, lowering it to $315 from $325, while maintaining an Outperform rating. The firm noted progress in Cigna's transition to a rebate-free Signature model and pharmacy network recontracting.

Risks

  • Deutsche Bank cited a lack of catalysts and suggested the company might lag behind other managed care organizations.
  • Wolfe Research lowered its price target from $325 to $315, indicating some caution despite the Outperform rating.

More from Insider Trading

Travere Therapeutics Director Roy D. Baynes Executes $225,000 Share Sale Under Pre-Arranged Plan Jun 16, 2026 Natera Chairman Executives Sell $21.4 Million in Shares Amid Market Activity Jun 16, 2026 Vistra Director Paul Barbas Executes Pre-Arranged Stock Sales Jun 16, 2026 Ring Energy CFO Singh Acquires Nearly $280K in Shares Amidst Earnings Beat Jun 16, 2026 Talkspace CLO John Reilly Sells $287,309 in Shares Jun 16, 2026